|
|
在研机构- |
原研机构- |
|
|
最高研发阶段批准上市 |
首次获批国家/地区- |
首次获批日期- |
|
作用机制adrenergic receptor激动剂 [+1] |
在研机构- |
|
在研适应症- |
|
最高研发阶段终止 |
首次获批国家/地区- |
首次获批日期- |
A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of C105 in Persons With Multiple Sclerosis With Cognitive Impairment
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
100 项与 Cognition Pharmaceuticals, LLC 相关的临床结果
0 项与 Cognition Pharmaceuticals, LLC 相关的专利(医药)
100 项与 Cognition Pharmaceuticals, LLC 相关的药物交易
100 项与 Cognition Pharmaceuticals, LLC 相关的转化医学